FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE OZURDEX™ (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein Anti-inflammatory. Dexamethasone is used to treat many inflammatory and autoimmune conditions, such as rheumatoid arthritis and bronchospasm. Idiopathic thrombocytopenic purpura, a decrease in numbers of platelets due to an immune problem, responds to 40 mg daily for four days; it may be administered in 14-day cycles. InjectIon technIques for OZURDEX® (Dexamethasone Intravitreal Implant) 0.7 mg Covered topics include: Profiles of the Experienced Injector Patient Preparation Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis Radiation Macular Edema after Ru106 Plaque Brachytherapy for Choroidal Melanoma Resolved by an Intravitreal Dexamethasone 0.7-mg Implant Indications and Usage Diabetic Macular Edema OZURDEX ® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema. OZURDEX® (dexamethasone) Intravitreal Implant. DESCRIPTION. OZURDEX ® is an intravitreal implant containing 0.7 mg (700 mcg) dexamethasone in the NOVADUR ® solid polymer sustained-release drug delivery system. Mohamed et al (2007) assessed the evidence for the effectiveness of interventions to improve visual acuity (VA) and prevent or treat neovascularization secondary to CRVO. Indications and Usage Diabetic Macular Edema. OZURDEX ® (dexamethasone intravitreal implant) is a corticosteroid indicated for the treatment of diabetic macular edema. OZURDEX must be administered by a qualified ophthalmologist experienced in intravitreal injections. Posology. The recommended dose is one OZURDEX implant to be administered intra-vitreally to the affected eye.